The sGC stimulator riociguat (BAY 63-2521) and the PDE5 inhibitor sildenafil, well-known modulators of the cGMP pathway, are clinically approved for the treatment of pulmonary arterial hypertension (PAH) [12, 13]. This evidence concerns the gene PDE5A and pulmonary arterial hypertension.